Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Idera Pharmaceuticals (NQ: IDRA )

4.480 USD +0.150 (+3.46%)
Official Closing Price Updated: 5:58 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Idera Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Idera Pharmaceuticals to Present at Upcoming Conferences
From GlobeNewswire News Releases
Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million
From GlobeNewswire News Releases
Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer
From GlobeNewswire News Releases
Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
ILLUMINATE-301 Continues on Track and Beyond Melanoma Strategy Advances 
From GlobeNewswire News Releases
Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037
– Protects Method-of-Use in CRC and HNSCC – 
From GlobeNewswire News Releases
Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
From GlobeNewswire News Releases
Idera Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update
Enhanced Financial Flexibility as ILLUMINATE-301 Continues on Track 
From GlobeNewswire News Releases
Thinking about buying stock in iBio Inc, Idera Pharmaceuticals, PDS Biotechnology, Checkpoint Therapeutics, or Norwegian Cruise Line Holdings?
InvestorsObserver issues critical PriceWatch Alerts for IBIO, IDRA, PDSB, CKPT, and NCLH. 
From PR Newswire
Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million
From GlobeNewswire News Releases
Idera Pharmaceuticals Announces Preliminary Data From and Planned Continuation of the ILLUMINATE-206 Trial for the Treatment of Micro-Satellite Stable Colorectal Cancer
From GlobeNewswire News Releases
Idera Pharmaceuticals Announces Change of Location for 2020 Annual Meeting of Stockholders
2020 Annual Meeting of Stockholders will be held in a virtual format 
From GlobeNewswire News Releases
Idera Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
Financial Resources Through Critical Catalyst of Phase 3 ORR Readout and Potentially Beyond 
From GlobeNewswire News Releases
Idera Pharmaceuticals Announces Tilsotolimod Program Updates to be Presented at AACR Virtual Annual Meeting 2020
From GlobeNewswire News Releases
Idera Pharmaceuticals Announces Final Clinical Safety and Efficacy Data from ILLUMINATE-204 Trial in Advanced Melanoma
From GlobeNewswire News Releases
Idera Pharmaceuticals Announces Private Placement of up to $20.7 Million
From GlobeNewswire News Releases
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
– Completed Enrollment in ILLUMINATE-301; Top-Line Overall Response Rate (ORR) Data Expected in Q1 2021 – 
From GlobeNewswire News Releases
Idera Pharmaceuticals Completes Enrollment in ILLUMINATE-301, its Registrational Trial of Tilsotolimod in Combination with Ipilimumab in Patients with Anti-PD-1 Refractory Advanced Melanoma
Overall Response Rate (ORR) Data Anticipated Q1 2021 
From GlobeNewswire News Releases
Idera Pharmaceuticals Provides 2020 Update and Outlook
Company to Present at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 7:30 AM PT/10:30 AM ET 
From GlobeNewswire News Releases
Idera Pharmaceuticals Announces Private Placement Up To $97.7 Million
From GlobeNewswire News Releases
Idera Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2019 Financial Results
From GlobeNewswire News Releases
Idera Pharmaceuticals Announces New U.S. Patent For Tilsotolimod Through September 2037
From GlobeNewswire News Releases
Idera Pharmaceuticals Announces Initiation of the ILLUMINATE-206 Trial Evaluating Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors
From GlobeNewswire News Releases
Idera Pharmaceuticals Announces Immuno-Oncology Clinical Research Collaboration with AbbVie
From GlobeNewswire News Releases
Idera Pharmaceuticals to Present at the Baird 2019 Global Healthcare Conference
From GlobeNewswire News Releases
Idera Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2019 Financial Results
From GlobeNewswire News Releases
Idera to Release 2019 Second Quarter Results on August 8, 2019
From GlobeNewswire News Releases
Idera Pharmaceuticals Announces Appointments of Elizabeth A. Tarka, MD, FACC as Chief Medical Officer and John J. Kirby as Chief Financial Officer
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced the appointments of Elizabeth A. Tarka, MD, FACC as Chief Medical Officer and the promotion of John J. Kirby to Chief Financial Officer. Dr.... 
From GlobeNewswire News Releases
Idera Pharmaceuticals to Present at the 2019 JMP Securities Life Sciences Conference
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the 2019 JMP Securities Life Sciences Conference on Thursday, June 20, 2019 at 1:30 p.m. Eastern Time at the... 
From GlobeNewswire News Releases
Idera Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drug candidates for... 
From GlobeNewswire News Releases
Repare Therapeutics Appoints Dr. Maria Koehler as Chief Medical Officer, Katina Dorton as Chief Financial Officer and Carol Schafer to its Board of Directors
Repare Therapeutics, a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in genetically defined patient populations,... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.